Arrowhead Pharma (ARWR) Stock Price, Quote & News

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitryp...

Industry: Biotechnology

Sector: Healthcare

Phone: 626 304 3400

Fax: 626 304 3401

Website: arrowheadpharma.com

Address:

177 East Colorado Boulevard, Suite 700, Pasadena, United States

cermakpool Jun. 24 at 10:40 PM

$ARWR My handle was Biotechprofiteer in 2015 on yahoo finance. Before Google’s censorship.

0 · Reply

cermakpool Jun. 24 at 10:38 PM

$ARWR Where is wyattcap?

0 · Reply

cermakpool Jun. 24 at 10:37 PM

$ARWR was $17 in October of 2014. The stock has done nothing in 10 years.

0 · Reply

cermakpool Jun. 24 at 10:29 PM

$ARWR What about the Hepatitis-B vaccine?

0 · Reply

johnnygogogo Jun. 24 at 7:34 PM

$ARWR Knock knock? Who’s there? Al. Al who? Al Go. Al Go Rhythm? No. Al Go who then? Al Go F#%! Yourself.

0 · Reply

BuyLogic_06x Jun. 24 at 7:09 PM

$ARWR

0 · Reply

LeftyT Jun. 24 at 5:59 PM

$ARWR Expansion in to the China market via the formation of Visirna has been under the radar since its formation. I get the feeling we will be hearing more about them in the near future. This could prove to be a massive deal down the road. Chris may end up looking like a genius soon. https://www.youtube.com/shorts/_34qzh8sr3I

0 · Reply

johnnygogogo Jun. 24 at 5:52 PM

$ARWR this just in… a new statement today from Chief Investment and Geometric Officer of ARWR, Johnny Ninedayema…

0 · Reply

WARBUD Jun. 24 at 4:59 PM

$ARWR Block out the noise. The charts look good and ARWR starting to get that look again. Held the pullback like a champ, sitting right on top of high volume support at 15.75 and buyers keep showing up. VWAP reclaim? Check. RSI curling up? Yup. ADX screaming strength on the 15min too. This thing’s tightening up and feels like it’s getting ready to move. Daily chart still clean. That 17.49 spot is the line in the sand clear it, and we’re probably seeing 18+ in a hurry. Just feels like it's loading. Squeeze is coiled tight. Not saying it goes tomorrow but when it goes… it goes. 15.23 is your support. Let’s see if it pops..

0 · Reply

skeezbag Jun. 24 at 3:08 PM

$ARWR lmfao the daily disconnect begins. Go fuck yourselves shareholders

0 · Reply

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jun 4, 2025, 8:02 AM EDT - 21 days ago

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Jun 2, 2025, 7:30 AM EDT - 23 days ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

May 29, 2025, 7:30 AM EDT - 27 days ago

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 12, 2025, 9:56 PM EDT - 6 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 7, 2025, 7:30 AM EDT - 7 weeks ago

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Apr 30, 2025, 4:01 PM EDT - 7 weeks ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Apr 15, 2025, 4:00 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Apr 4, 2025, 4:30 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Mar 21, 2025, 5:56 PM EDT - 3 months ago

Arrowhead Pharmaceuticals Is Finally Arriving

Mar 10, 2025, 7:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Mar 6, 2025, 8:45 AM EST - 3 months ago

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Feb 28, 2025, 9:00 AM EST - 4 months ago

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Feb 25, 2025, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Feb 19, 2025, 11:53 AM EST - 4 months ago

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Feb 19, 2025, 10:41 AM EST - 4 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

AZN BHVN KROS LLY NVO REGN SRRK

Feb 18, 2025, 10:20 AM EST - 4 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

AUB CRK CYTK EXE KRYS MARA MP

Feb 10, 2025, 9:35 PM EST - 4 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Feb 10, 2025, 4:01 PM EST - 4 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Feb 10, 2025, 8:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

SRPT

Jan 22, 2025, 5:54 PM EST - 5 months ago

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

B GWRE

Jan 22, 2025, 4:00 PM EST - 5 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Jan 17, 2025, 4:30 PM EST - 5 months ago

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Dec 23, 2024, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Dec 11, 2024, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Dec 3, 2024, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Dec 2, 2024, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Nov 26, 2024, 11:08 PM EST - 7 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript

Nov 26, 2024, 4:00 PM EST - 7 months ago

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Nov 26, 2024, 7:00 AM EST - 7 months ago

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

SRPT

Nov 18, 2024, 7:31 AM EST - 7 months ago

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Nov 18, 2024, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

Nov 5, 2024, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

Nov 4, 2024, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

Nov 1, 2024, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

Sep 23, 2024, 7:30 AM EDT - 9 months ago

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Sep 10, 2024, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Sep 3, 2024, 11:01 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Sep 2, 2024, 6:36 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Aug 21, 2024, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Aug 14, 2024, 6:59 PM EDT - 11 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript)

Aug 14, 2024, 1:30 PM EDT - 11 months ago

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

Aug 8, 2024, 4:01 PM EDT - 11 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

Aug 8, 2024, 4:00 PM EDT - 11 months ago

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

Jul 26, 2024, 12:12 PM EDT - 11 months ago

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 24, 2024, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

Jun 25, 2024, 2:01 PM EDT - 1 year ago

Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course

AGR

Jun 25, 2024, 1:55 PM EDT - 1 year ago

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

Jun 24, 2024, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE

cermakpool Jun. 24 at 10:40 PM

$ARWR My handle was Biotechprofiteer in 2015 on yahoo finance. Before Google’s censorship.

0 · Reply

cermakpool Jun. 24 at 10:38 PM

$ARWR Where is wyattcap?

0 · Reply

cermakpool Jun. 24 at 10:37 PM

$ARWR was $17 in October of 2014. The stock has done nothing in 10 years.

0 · Reply

cermakpool Jun. 24 at 10:29 PM

$ARWR What about the Hepatitis-B vaccine?

0 · Reply

johnnygogogo Jun. 24 at 7:34 PM

$ARWR Knock knock? Who’s there? Al. Al who? Al Go. Al Go Rhythm? No. Al Go who then? Al Go F#%! Yourself.

0 · Reply

BuyLogic_06x Jun. 24 at 7:09 PM

$ARWR

0 · Reply

LeftyT Jun. 24 at 5:59 PM

0 · Reply

johnnygogogo Jun. 24 at 5:52 PM

$ARWR this just in… a new statement today from Chief Investment and Geometric Officer of ARWR, Johnny Ninedayema…

0 · Reply

WARBUD Jun. 24 at 4:59 PM

0 · Reply

skeezbag Jun. 24 at 3:08 PM

$ARWR lmfao the daily disconnect begins. Go fuck yourselves shareholders

0 · Reply

skeezbag Jun. 24 at 12:53 PM

$ARWR who is ready for the same fucking chart today? Yesterday had more than half of the volume in the fraud dark pools

0 · Reply

cermakpool Jun. 24 at 12:08 PM

$ARWR My posts get deleted on Yahoo Finance. I am Jerry062425 over there. I speak about the relationship between Stone Age arrowheads made of obsidian and arrowhead the company. I know about Doctor Anal Zone.(Anzalone) and how he killed many chimpanzees by infecting them with hepatitis.

3 · Reply

CarverX Jun. 24 at 3:09 AM

$ARWR $WGS 😎 Where’s Holden?

0 · Reply

WARBUD Jun. 23 at 11:08 PM

$ARWR 3 to 1 sell vs buy. Thats crazy. Lots of games getting played at this level...heavy on the ask side. Not chasing but definitely on radar..

0 · Reply

skeezbag Jun. 23 at 7:38 PM

$ARWR 11am and 330 shareholders can fuck themselves 🤖🤖👾👾

0 · Reply

skeezbag Jun. 23 at 5:40 PM

$ARWR close below 15.28 is the next mark for the amazing make the chart look like shit algo I ahould get a job at blackrock with all the other retarded and washed up doctors/scientists

1 · Reply

skeezbag Jun. 23 at 4:54 PM

$ARWR weird this chart looks fucking familiar

0 · Reply

johnnygogogo Jun. 23 at 3:18 PM

$ARWR taking a poll. Who sucks more, Adam Feuerstein or Adam Feuerstein?

3 · Reply

skeezbag Jun. 23 at 2:41 PM

$ARWR its 11am. The russell robot says go fuck yourselves shareholders

1 · Reply

R33dh Jun. 23 at 11:44 AM

$ARWR 🤷🏼‍♂️ https://www.businesswire.com/news/home/20250623551409/en/Arrowhead-Pharmaceuticals-Completes-Enrollment-in-SHASTA-3-SHASTA-4-and-MUIR-3-Phase-3-Studies-of-Plozasiran

0 · Reply

CH_Expat Jun. 21 at 5:51 PM

$IDYA $ARWR $SNDX $GMAB are my current holdings in descending order. Watch-Shortlist (buying when cheaper) in urgency order: MLTX, TARS, ARQT, MRUS, APGE

0 · Reply

johnnygogogo Jun. 20 at 6:38 PM

$ARWR will post this every quarter on rebalance day to see if Punxsutawny Phil sees his shadow or not.

1 · Reply

Market Cap	2.14B
Revenue (ttm)	3.55M
Net Income (ttm)	-599.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	156.04
Profit Margin	-16,887.04%
Debt to Equity Ratio	0.40

Volume	1,324,300
Avg Vol	1,729,030
Day's Range	N/A - N/A
Shares Out	138.10M
Stochastic %K	40%
Beta	0.96
Analysts	Strong Sell
Price Target	$44.00